Interview with Kheng Hoe, Kwa, Managing Director, Nycomed Malaysia
Before joining Nycomed you spent a year working at the Drug Control Authority (DCA). What did your regulatory friends say when you told them you were off to join the…
Address: Lot 3A-01, Level 3A, Block B, HP Towers 12, Jalan Gelenggang , Bukit Damansara, 50490 Kuala Lumpur, Malaysia
Tel: +6 3 2093 1119
Web: http://www.tpi.takeda.com/
Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries.
Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America.
In 2009, total sales reached € 3.2 billion, with an adjusted EBITDA of € 1.1 billion. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines.
Nycomed’s differentiated portfolio of branded medicines is focused on gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Before joining Nycomed you spent a year working at the Drug Control Authority (DCA). What did your regulatory friends say when you told them you were off to join the…
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Dr Hyzan Mohd Yusof, CEO at OSA Technology, tells the story of how he founded the company to address Malaysia’s unmet needs in medical devices as well as his vision…
How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia. Inno Bio Ventures, a Malaysian state-owned company originally set up to create…
Dr Ramli Zainal, the director at National Pharmaceutical Regulatory Agency (NPRA), expresses the continuous work of NPRA to build a strong regulatory ecosystem in Malaysia and the important role that…
Tan Sri Rahman Mamat, chairman of Inno Bio Ventures, provides his vision for biosimilars’ potential in Malaysia, and the progress the company has made in laying the foundations to make…
George Kazzi, general manager of Baxter Malaysia, highlights the main areas of development for his affiliate, including the introduction of more renal dialysis innovation as well as increasing awareness and…
Dr Dhesi Baha Raja, consultant in digital technologies at the Malaysian Ministry of Health, introduces the government’s plan to enter digital health through electronic medical records (EMR) and shares his…
Kshitij Panse, director of Servier Malaysia discusses the company’s planned move into oncology, as well as their strategies to provide an all-round improved patient experience, through education, screening, and e-health.…
Datuk Dr Noor Hisham Abdullah, director general of health at the Ministry of Health of Malaysia unveils the government’s plan to bring healthcare back to the community, and create a…
Dr. Azrul Mohd Khalib, chief executive at the Galen Centre for Health and Social Policy, gives an insight on the current important issues the Malaysian healthcare ecosystem is facing and…
Malaysia’s multi-ethnic population, disease burden, medical infrastructure and research speed, combined with its population’s proficiency in English, make the Southeast Asian nation a potentially excellent regional clinical trials destination. …
Shahnas Oli Mohamed, the managing director of Natural Wellness Holdings Sdn Bhd, expresses the important work that Natural Wellness has done to provide natural healthcare products to Malaysian patients, including…
See our Cookie Privacy Policy Here